AM 103 is a potent and selective FLAP inhibitor, with an IC50 value of 4.2 nM.

L-Buthionine-(S,R)-sulfoximine is a cell-permeable, potent, fast acting and irreversible inhibitor of g-glutamylcysteine synthetase and depletes cellular glutathione levels. The IC50 value of L-Buthionine-(S,R)-sulfoximine on melanoma, breast and ovarian tumor specimens are 1.9 μM, 8.6 μM, and 29 μM, respectively.

Ticagrelor is the first reversibly binding oral P2Y12 receptor antagonist, also inhibits CYP2C9 and 4-hydroxylation with IC50 of 10.5 μM and 8.2 μM respectively.

DS-437 is a potent, selective, dual inhibitor of PRMT5 and PRMT7 with IC50 of 6.0 uM for both, DS-437 is inactive against 29 other human protein-, DNA-, and RNA-methyltransferases.

Depatuxizumab Mafodotin (Depatux-M, ABT-414) is an antibody-drug conjugate consisting of an EGFR IGg1 monoclonal antibody conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link. Depatuxizumab Mafodotin is used in the treatment of recurrent EGFR-amplified Glioblastoma (GBM).

TL 13-27 is a negative control for TL 12-186. Demonstrates no kinase degradation in vitro.

Apilimod(STA 5326) mesylate is a potent IL-12/IL-23 inhibitor, IL-12 production in cultures of IFN-r/LPS–stimulated human PBMCs is strongly inhibited by STA-5326 with an IC50 of 10 nM.

Apremilast(CC10004) is a novel small molecule inhibitor of PDE4 with an IC50 value of 74 nM.

Bevurogant is a retinoid-related orphan receptor-gamma t (RORγt) antagonist. Bevurogant can be used for the research of chronic inflammatory diseases.

DS18561882 is a potent and isozyme-selective MTHFD2 inhibitor with GI50 of 140 nM, which also shows good oral pharmacokinetic profile.

Ziftomenib is a menin-MLL interaction inhibitor with antitumor activities (WO2017161028A1, compound 151).

Ibutamoren mesylate (MK-0677) is an orally active nonpeptide growth hormone (GH) secretagogue.

β-Amyloid (25-35) (Amyloid beta-peptide (25-35), Aβ25-35, β-Amyloid peptide (25-35)) , a sequence GSNKGAIIGLM, is a highly toxic synthetic derivative of Amyloid beta-peptide (Aβ-peptides) which forms fibrillary aggregates. β-Amyloid (25-35) is involved in the pathogenesis of Alzheimer's disease.

N-Formyl-Met-Leu-Phe, also known as fMLF, is a potent neutrophil chemoattractant and the reference agonist for the G protein-coupled N-formylpeptide receptor (FPR).

Exatecan mesylate is a semisynthetic, water-soluble derivative of camptothecin with antineoplastic activity.

Fexinidazole is a new Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness

Nonapeptide-1 (Melanostatine-5), a peptide hormone, is a selective antagonist of MC1R (Ki: 40 nM). Nonapeptide-1 is a competitive α-MSH antagonist that potently inhibits intracellular cAMP and melanosome dispersion induced by α-MSH in melanocytes (IC50: 2.5 nM and 11 nM, respectively). Nonapeptide-1 inhibits melanin synthesis, and can be used in the research of skin pigmentation and regulation of steroid production in the adrenal gland, skin cancer.

MOTS-c, a mitochondria-derived peptide (MDP), exerts antinociceptive and anti-inflammatory effects through activating AMPK pathway and inhibiting MAP kinases-c-fos signaling pathway.

Glecaprevir is a novel HCV NS3/4A protease inhibitor, with IC50 values ranging from 3.5 to 11.3 nM.

Danoprevir is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A.

Zandatrigine is a sodium channel protein type 8 subunit alpha (Scn8α) blocker.

MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.

AMI-1 is a PRMT and HIV-1 RT polymerase inhibitor.

Alofanib ((RPT-835) is a potent, selective, allosteric FGFR2 inhibitor that significantly inhibits bFGF-induced proliferation of HUVEC cells with IC50 of 11 nM

Argatroban monohydrate is a direct, selective thrombin inhibitor.

ASP3026 is a novel and selective inhibitor for ALK with IC50 of 3.5 nM.

KN-62 is a sective, cell-permeable inhibitor of CaM kinase II (IC50 = 0.9 μM).

Cintirorgon (LYC-55716) is novel oral RAR-related orphan receptor γ (RORγ) agonist.

BI-78D3 is a competitive c-Jun N-terminal kinase (JNK) inhibitor (IC50 = 280 nM) that displays > 100 fold selectivity over p38α and no activity at mTOR and PI-3K.